Minerva Neurosciences Appoints Dr. Gail M. Farfel to Strengthen Leadership for Phase 3 Trials

Neurvati Neurosciences Enhances Leadership with Dr. Gail M. Farfel’s Appointment

Neurvati Neurosciences, a clinical-stage biotechnology firm dedicated to developing therapies for neurological and psychiatric disorders, strengthens its leadership with the addition of Dr. Gail M. Farfel to its board of directors. This strategic move aligns with the company’s upcoming pivotal Phase 3 trial for radiprodil, which targets GRIN-related neurodevelopmental disorders (GRIN-NDD). Deborah Dunsire, MD, who serves as Board Chairwoman for both Neurvati and GRIN Therapeutics, highlights Dr. Farfel's extensive experience in neuroscience research, which spans over three decades. Her knowledge is expected to significantly benefit the companies as they aim to advance their innovative treatments in a competitive landscape.

Dr. Farfel's impressive career includes leadership roles at esteemed organizations such as Zogenix, Novartis, and Pfizer. Previously, she held the position of CEO at ProMIS Neurosciences. Her contributions to the field are substantial, with over 50 scientific publications in neuropsychopharmacology. This combination of practical experience and academic excellence positions her as a valuable asset as Neurvati and GRIN navigate the complexities of clinical trials and regulatory pathways. Dr. Farfel's enthusiasm for accelerating the development of novel therapies is palpable, particularly in light of the promising data regarding radiprodil and the collaboration with Angelini Pharma, which broadens their global operational reach.

As Neurvati and GRIN Therapeutics embark on this significant growth phase, Dr. Farfel's insights will be crucial for steering the companies through the challenges of bringing first-in-class treatments to market. The recent Series D financing and a licensing agreement underscore the momentum behind their efforts. With Dr. Farfel on board, both organizations are better positioned to address the urgent needs of individuals suffering from GRIN-NDD and other serious neurodevelopmental disorders, fostering hope for improved patient outcomes in the field of neuroscience.

In addition to Dr. Farfel's appointment, the collaborative efforts between Neurvati and GRIN Therapeutics signify a commitment to innovation in the treatment of complex neurological conditions. The partnership not only amplifies their capabilities but also underscores the importance of interdisciplinary cooperation in advancing healthcare solutions. As the companies move forward, the integration of Dr. Farfel’s expertise is likely to catalyze further advancements in their therapeutic pipelines.